These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 300513)
1. Effect of exercise on F VIII-complex: proportional increase of ristocetin cofactor (Von Willebrand factor) and F VIII-AGN, but disproportional increase of F VIII-AHF. Stibbe J Thromb Res; 1977 Jan; 10(1):163-8. PubMed ID: 300513 [No Abstract] [Full Text] [Related]
2. Effect of exercise on the factor VIII complex: a correlation of the Von Willebrand antigen and factor VIII coagulant antigen increase. Brown JE; Baugh RF; Hougie C Thromb Res; 1979; 15(1-2):61-7. PubMed ID: 314688 [No Abstract] [Full Text] [Related]
3. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. Weiss HJ; Sussman II; Hoyer LW J Clin Invest; 1977 Aug; 60(2):390-404. PubMed ID: 17621 [TBL] [Abstract][Full Text] [Related]
4. Willebrand factor and ristocetin. II. Relationship between Willebrand factor, Willebrand antigen and factor VIII activity. Meyer D; Jenkins CS; Dreyfus MD; Fressinaud E; Larrieu MJ Br J Haematol; 1974 Dec; 28(4):579-99. PubMed ID: 4549013 [No Abstract] [Full Text] [Related]
5. Proceedings: Interaction of ristocetin (R), von Willebrand factor (vWF), factor VIII clotting activity (VIIIc) and platelets. Zucker MB; McPherson J; Kim SJ; Macdonald VE; Taylor D; Johnson AJ; Barlow GH Thromb Diath Haemorrh; 1975 Nov; 34(2):582. PubMed ID: 1081748 [No Abstract] [Full Text] [Related]
6. Preferential binding of high molecular weight forms of von Willebrand factor to fibrillar collagen. Santoro SA Biochim Biophys Acta; 1983 Mar; 756(1):123-6. PubMed ID: 6402037 [TBL] [Abstract][Full Text] [Related]
7. Effect of exercise, DDAVP, and epinephrine on the factor VIII:C/von Willebrand factor complex in normal dogs and von Willebrand factor deficient Doberman pinscher dogs. Meyers KM; Wardrop KJ; Dodds WJ; Brassard J Thromb Res; 1990 Jan; 57(1):97-108. PubMed ID: 2105540 [TBL] [Abstract][Full Text] [Related]
8. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content. Weiss HJ; Hoyer LW; Rickles FR; Varma A; Rogers J J Clin Invest; 1973 Nov; 52(11):2708-16. PubMed ID: 4542944 [TBL] [Abstract][Full Text] [Related]
9. Antibody-induced von Willebrand syndrome: inhibition of VIII VWF and VIII AGN with sparing of VIII AHF by the autoantibody. Gazengel C; Prieur AM; Jacques C; Buriot D; Nedellec J; Josso F Am J Hematol; 1978; 5(4):355-63. PubMed ID: 313704 [No Abstract] [Full Text] [Related]
10. Electrophoretic heterogeneity of normal factor VIII/Von Willebrand protein, and abnormal electrophoretic mobility in patients with Von Willebrand's disease. Sultan Y; Simeon J; Caen JP J Lab Clin Med; 1976 Feb; 87(2):185-94. PubMed ID: 1082003 [TBL] [Abstract][Full Text] [Related]
11. Exercise-induced changes of Factor VIII complex in healthy subjects and in type-I diabetics: relation between growth hormone and Von Willebrand Factor increments. Trovati M; Tamponi G; Marra S; Lorenzati R; Schinco P; Bazzan M; Vitali S; Cavalot F; Pagano G; Lenti G Horm Metab Res; 1983 Jul; 15(7):316-20. PubMed ID: 6411576 [TBL] [Abstract][Full Text] [Related]
12. Factor VIII (Willebrand) antigen and ristocetin-Willebrand factor in pigs with von Willebrand's disease. Fass DN; Brockway WJ; Owen CA; Bowie EJ Thromb Res; 1976 Mar; 8(3):319-27. PubMed ID: 1083569 [No Abstract] [Full Text] [Related]
13. Interactions of purified rat factor VIII/von Willebrand factor with rat and human platelets--effect of albumin and ristocetin. Dejana E; Furlan M; Barbieri B; Donati MB; Beck EA Thromb Haemost; 1984 Aug; 52(1):57-9. PubMed ID: 6437011 [TBL] [Abstract][Full Text] [Related]
14. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand's disease. Mannucci PM; Canciani MT; Rota L; Donovan BS Br J Haematol; 1981 Feb; 47(2):283-93. PubMed ID: 6781527 [TBL] [Abstract][Full Text] [Related]
15. Antihemophilic factor concentrate therapy in von Willebrand disease. Dissociation of bleeding-time factor and ristocetin-cofactor activities. Blatt PM; Brinkhous KM; Culp HR; Krauss JS; Roberts HR JAMA; 1976 Dec; 236(24):2770-2. PubMed ID: 1086910 [TBL] [Abstract][Full Text] [Related]
16. The spectrum of von Willebrand's disease revisited. Bowie EJ; Fass DN; Olson JD; Owen CA Mayo Clin Proc; 1976 Jan; 51(1):35-41. PubMed ID: 765637 [TBL] [Abstract][Full Text] [Related]
17. Effects of various agents on ristocetin-Willebrand factor activity in long-term cultures of von Willebrand and normal human umbilical vein endothelial cells. Booyse FM; Osikowicz G; Feder S Thromb Haemost; 1981 Oct; 46(3):668. PubMed ID: 6976017 [No Abstract] [Full Text] [Related]
18. Identical binding site on human platelets for von Willebrand factor and bovine platelet aggregating factor. Suzuki K; Nishioka J; Hashimoto S Thromb Res; 1980 Jan 1-15; 17(1-2):215-23. PubMed ID: 6769177 [No Abstract] [Full Text] [Related]
19. Adsorption of von Willebrand factor/factor VIII by the genetically distinct interstitial collagens. Santoro SA Thromb Res; 1981 Mar; 21(6):689-91. PubMed ID: 6791300 [No Abstract] [Full Text] [Related]
20. Enzymatic degradation of the factor-VIII-von-Willebrand protein: a unique tryptic fragment with ristocetin cofactor activity. Martin SE; Marder VJ; Francis CW; Loftus LS; Barlow GH Blood; 1980 May; 55(5):848-58. PubMed ID: 6767513 [No Abstract] [Full Text] [Related] [Next] [New Search]